- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Concerns Are Raised About Actions Limiting Drug Supply Amid COVID-19
Private and public institutions are trying to secure supplies of drugs and pharmaceuticals amid travel restrictions and border controls imposed by coronavirus disease 2019 (COVID-19).
Aware that travel restrictions and border controls imposed by coronavirus disease 2019 (COVID-19) pose a threat to drug supply, the International Generic and Biosimilar Medicines Association (IGBA) is working to establish priority designations for medicines in air and sea cargo transport.
The move is among diverse attempts by private and public institutions recently to secure supplies of drugs and pharmaceuticals amid the dizzying pace of events. “The situation is constantly and rapidly changing,” said Suzette Kox, secretary general of IGBA, in an interview with The Center for Biosimilars.
In recent days, many have spoken out against export curbs and other protectionist measures that threaten to upset the balance of international healthcare. Some actions by governments have involved instating emergency powers to bypass patent exclusivity protections where necessary.
To read the rest of the story visit The Center for Biosimilars.
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
